Loading
A phase 3 trial of Sonrotoclax, Zanubrutinib, Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia is a phase 3 interventional study registered as NCT07277231 by BeOne Medicines, with 500 participants planned, started 2026-01-22 and due to reach its primary completion in 2031-02. Interventions recorded: Sonrotoclax, Zanubrutinib, Acalabrutinib and Venetoclax.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.